Cytheris Announces Phase I Study of Interleukin-7 as Immunotherapy in Treatment of Immunodeficient Transplant Recipients
News Apr 24, 2008
Cytheris SA has announced the initiation of a Phase I clinical trial of its lead investigational drug candidate, Interleukin-7 (IL-7), also known as CYT107. This new trial will study the use of IL-7 / CYT107 in the treatment of post-transplant patients with T-cell depleted bone marrow or peripheral blood stem cell transplants.
The initial study site will be at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, where Marcel R.M. van den Brink, M.D., Ph.D., Head, Division of Hematologic Oncology, and Miguel-Angel Perales, M.D., Assistant Attending Physician in the Bone Marrow Transplant Service, will serve as Principal Investigator and co-Principal Investigator, respectively. Additional study sites are expected to open in the United States during the coming months.
Recombinant human Interleukin-7 (r-hIL-7) is a critical growth factor for immune T-cell recovery and enhancement. Clinical trials conducted on more than 75 patients in Europe, the United States and Canada have suggested the potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells. Cytheris is currently conducting multiple international clinical studies of IL-7 in HIV, HCV and cancer.
"We share a commitment with MSKCC to addressing the unmet medical need that exists for cancer patients who are frequently in a profoundly immunodeficient state following the bone marrow transplant procedure, leaving them susceptible to a variety of bacterial, viral, and fungal infections," said Michel Morre, DVM, President and CEO of Cytheris.
"MSKCC has for many years been in the forefront of stem cell transplantation therapy in the U.S. and we are therefore especially pleased that Drs van den Brink and Perales have agreed to participate in this study which we hope will ultimately lead to the development of therapies to prevent post-transplant infections which so often contribute to the failure of hematopoietic stem cell allografts."
Regenerative Medicine Meets Clever Engineering to Accommodate Bone GraftsNews
Personalized bone grafts developed to repair bone defects from disease or injuryREAD MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Protein Essential for Making Stem Cells IdentifiedNews
The discovery by Stanford scientists drills a peephole into the black box of cellular reprogramming and may lead to new ways to generate induced pluripotent stem cells in the laboratory.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019